Practical implementation of the continual reassessment method

Handbook of Statistics in Clinical Oncology: Second Edition

Volumn , Issue , 2005, Pages 97-116

  Ishizuka, Naoki ^a   Morita, Satoshi ^b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123816656     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (24)

1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990;46(1):33-48.
2. Ishizuka N, Ohashi Y. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Stat. Med. 2001; 20(17-18): 2661-2681.
3. Piantadosi S. Clinical Trials. 1997 John Wiley and Sons, New York.
4. Green S, Benedetti J, Crowley J. Clinical Trials in Oncology. 2nd ed. (Interdisciplinary Statistics S.) 2003, Chapman & Hall/CRC.
5. Horowitz MM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
6. Kolbs HJ, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
7. Collins RH, et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft versus leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992;10:391-395.
8. Porter DL, Connors JM, Van Deerlin VM, Duffy KM, McGarigle C, Saidman SL, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J. Clin. Oncol. 1999;17(4):1234.
9. O'Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat. Med. 1991;10(11):1647-1664.
10. Gasparini M, Eisele J. A curve-free method for phase I clinical trials. Biometrics. 2000;56(2):609-615.
11. Legedza AT, Ibrahim JG. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method. Stat. Med. 2001;20(6):867-882.
12. Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J. Biopharm. Stat. 1994;4(2):147-164.
13. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM. A comparison of two phase I trial designs. Stat. Med. 1994;13(18):1799-1806.
14. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 1995;14(11):1149-1161.
15. Piantadosi S, Liu G. Improved designs for dose escalation studies using pharmacokinetic measurements. Stat. Med. 1996;15(15):1605-1518.
16. Ahn C. An evaluation of phase I cancer clinical trial designs. Stat. Med. 1998;17(14):1537-1549.
17. Heyd JM, Carlin BP. Adaptive design improvements in the continual reassessment method for phase I studies. Stat. Med. 1999;18(11):1307-1321.
18. Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. Stat. Med. 1999;18(10):1155-1169.
19. Cheung YK, Chappell R. A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics. 2002;58(3):671-674.
20. O'Quigley J, Reiner E. A stopping rule for continual reassessment method. Biometrika 1998;85:741-748.
21. O'Quigley J. Continual reassessment designs with early termination. Biostatistics. 2002;3(1):87-99.
22. O'Quigley J, Shen LZ, Gamst A. Two-sample continual reassessment method. J. Biopharm. Stat. 1999;9(1):17-44.
23. O'Quigley J, Paoletti X. Continual reassessment method for ordered groups. Biometrics. 2003;59(2):430-140.
24. Gilks W.R., Richardson S., Spielgelhalter D.J. Markov Chain Monte Carlo in Practice. (Interdisciplinary Statistics S.) 1995, Chapman & Hall/CRC.